Suraksha Diagnostic Limited

Healthcare · Healthcare Services

NSE: SURAKSHA BSE: 544293
₹355.40
▲ 0.35 (0.10%)
Sept. 30, 2026 · NSE · nse_bhavcopy
Quality
65/100
Moderate
Valuation
—/100
Expensive
Momentum
55/100
Neutral

QVM read Mixed signals Quality Moderate, Valuation Expensive, Momentum Neutral

Tradinity's own scoring, not a copy of any third party's -- see the Key Metrics section for the real ratios behind each number.

Key Metrics

Market Capitalization
₹1,851 Cr
PE (TTM)
50.3
Industry median 50.2 (44 companies)
Price to Book
7.6
PEG (TTM)
8.4
Institutions holding %
36.70%
FII + DII, latest filed period
Piotroski Score
5
Relative return vs Nifty50, qtr %
35.0
Relative return vs Sector, qtr %
35.5
Free Cash Flow
₹14 Cr
as of March 31, 2026
Industry median ₹1 Cr (75 companies)
EPS Growth (YoY)
28.04%
as of June 30, 2026
Industry median 13.27% (57 companies)
Net Profit Growth (TTM)
5.25%
as of June 30, 2026
Industry median 7.21% (57 companies)
Operating Revenue Growth (TTM)
21.45%
as of June 30, 2026
Industry median 12.82% (57 companies)
Profit Growth (YoY)
27.75%
as of June 30, 2026
Industry median 8.53% (57 companies)
Revenue Growth (YoY)
19.65%
as of June 30, 2026
Industry median 18.84% (52 companies)
Current Ratio
1.05
as of March 31, 2026
Industry median 2.06 (74 companies)
Debt to Equity
0.01
as of March 31, 2026
Industry median 0.11 (62 companies)
Interest Coverage
4.77
as of June 30, 2026
Industry median 7.94 (57 companies)
Net Margin
14.96%
as of June 30, 2026
Industry median 9.88% (61 companies)
Operating Margin (EBIT)
23.64%
as of June 30, 2026
Industry median 17.21% (61 companies)
Operating Margin (TTM)
20.24%
as of June 30, 2026
Industry median 16.20% (59 companies)
Return on Assets
6.99%
as of March 31, 2026
Industry median 5.40% (58 companies)
Return on Capital Employed
14.20%
as of March 31, 2026
Industry median 10.44% (56 companies)
Return on Equity
12.87%
as of March 31, 2026
Industry median 10.16% (58 companies)

Investment checklist

Tradinity's own yes/no questions with the rule stated beside each. “Items without enough data are left out, never counted as a No, and the totals count only answered questions. A summary of numbers on this page, not advice.

Financials

4 of 8 met
  • No Net profit is higher than a year earlier in each of the last 4 quarters
  • Yes Revenue is higher than a year earlier in each of the last 4 quarters
  • No Quality score is Strong (70 or more)
  • No Piotroski F-score is 7 or more (score 5)
  • Yes Debt to equity is below 0.5 (0.01)
  • No Return on equity is 15% or more (12.9%)
  • Yes Net cash flow for the latest year is positive
  • Yes Cash from operations is higher than the year before

Ownership

4 of 4 met
  • Yes FII/FPI or DII holding rose in the latest quarter
  • Yes Promoter holding rose or was unchanged in the latest quarter
  • Yes Promoter pledge is 5% of their holding or less and not rising (0.1% pledged)
  • Yes Insiders have not sold in the past 3 months (no open-market sale filed in the last 3 months)

Peer comparison

3 of 3 met
  • Yes 1-year return beats the industry median
  • Yes Revenue growth beats the industry median
  • Yes Profit growth beats the industry median

Value and momentum

2 of 6 met
  • No Price sits in the Buy zone of its own historical PE range (Overvalued (above its own historical PE range))
  • No Valuation score is Undervalued (70 or more)
  • No Momentum score is Bullish (70 or more)
  • Yes Price is above the 5, 10 and 20 day averages
  • Yes Price is above the 50, 100 and 200 day averages
  • No Latest candle has a bullish shape (hammer, dragonfly doji, white marubozu)

Price

Download CSV

PE/EPS use each quarter's real filed EPS only from 45 days after quarter-end (no look-ahead) against the raw close of the day. Price-to-book isn't a mode here: the feed has no dated share count, so there's no real history to chart.

RSI (14) (same adjusted close series as the price chart above)

MACD (12, 26, 9) (same adjusted close series as the price chart above)

Relative Returns (vs NIFTY 50)

Prices adjusted for splits and bonuses. * = a corporate action affecting this date could not be parsed and is not reflected.

Price range

Day return
0.1%
Low 350.1000 · High 357.6000
1W return
0.0%
Low 335.0000 · High 359.4000
1M return
5.0%
Low 300.0000 · High 360.0000
52W return
19.5%
Low 224.1000 · High 360.0000
Lifetime High ₹418.6500 (Dec. 16, 2024)
Lifetime Low ₹227.9500 (March 30, 2026)

Full price history and technicals →

EMA & SMA

Bullish6
Bearish0
5D
351.8
10D
347.8
20D
339.9
50D
318.4
100D
301.3
200D
282.3

Delivery and volume

Day avg. delivery
47.6%
Week avg. delivery
55.2%
Month avg. delivery
55.5%

Week = 5 sessions, Month = 22 sessions ending the latest trading day — the same combined NSE+BSE delivery data as the table below, just summed.

Resistance and support

354.37
Pivot
First resistance358.63
Second resistance361.87
Third resistance366.13
First support351.13
Second support346.87
Third support343.63
Day RSI65.9
Day MFI74.6
Day MACD11.34
Day MACD signal11.62

Beta

1M-0.01
3M0.10
1Y0.42
3Y0.65

Price change analysis

↑ 5.0%
Over 1 Month
LowHigh
300.00360.00
↑ 32.7%
Over 3 Months
LowHigh
240.40360.00
↑ 44.9%
Over 6 Months
LowHigh
237.32360.00
↑ 19.5%
Over 1 Year
LowHigh
224.10360.00
Legend Positive indicator Neutral indicator Negative indicator

Buy/Sell Zone

View Buy/Sell Zone →
Current PE 50.3 (own history: 34.9–48.8)
Overvalued (above its own historical PE range)
Revenue (June 30, 2026)
₹84 Cr
Net profit (June 30, 2026)
₹13 Cr
Basic EPS (June 30, 2026)
₹2.4200

Ranks #27 of 62 in Healthcare Services by market cap -- full peer table on the Financials page.

Shareholding pattern / Ownership

Shareholding summary

Jun 2026
  • Promoter49.10%
  • Mutual funds20.05%
  • FII/FPI13.47%
  • Other DII3.18%
  • Public14.20%

Largest holders

NameCategoryShares %Shares
RITU MITTALPromoter15.9300%8295437
ORBIMED ASIA II MAURITIUS LIMITEDPublic12.8800%6706711
SATISH KUMAR VERMAPromoter10.8400%5643971
SARLA KEJRIWALPromoter9.2300%4809062
NIPPON LIFE INDIA TRUSTEE LTD-A/C NIPPON INDIA PHAPublic7.4800%3896349

As of June 30, 2026. Only holders the filing discloses individually.

Historical promoter holding

Promoters holdings were unchanged at 49.10% in Jun 2026 qtr

Historical fii holding

FII/FPI holdings increased from 13.46% to 13.47% in Jun 2026 qtr

Historical mutual fund holding

Mutual funds holdings increased from 19.79% to 20.05% in Jun 2026 qtr

4 mutual fund schemes also hold this stock.

All shareholding details →

Insider trading, SAST & pledges

All 17 insider trades, 19 SAST, 0 pledge events →

Latest insider trades

FiledPersonCategoryTypeQuantityValue
25 Feb 2026 Aparajita Chatterjee Promoter group Buy 0 ₹0
24 Feb 2026 Aparajita Chatterjee Promoter group Buy 0 ₹0
24 Feb 2026 Aparajita Chatterjee Promoter group Buy 0 ₹0
20 Feb 2026 Aparajita Chatterjee Promoter group Buy 0 ₹0
19 Feb 2026 Aparajita Chatterjee Promoter group Buy 0 ₹0
10 Dec 2025 Bipul Mittal Promoter group Buy 0 ₹0
10 Dec 2025 Bipul Mittal HUF Promoter group Buy 0 ₹0
29 Sep 2025 Ritu Mittal Promoter Buy 0 ₹0
18 Aug 2025 Dr. Somnath Chatterjee Promoter Buy 0 ₹0
14 Aug 2025 Dr. Somnath Chatterjee Promoter Buy 0 ₹0

All insider and SAST disclosures →

DateClientDealActionQuantityPriceExchange
27 May 2025 BNP PARIBAS FINANCIAL MARKETS Block Buy 296,032 338.0000 BSE
27 May 2025 INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. Block Sell 296,032 338.0000 BSE
27 May 2025 INTEGRATED CORE STRATEGIES (ASIA) PTE. LTD. Bulk Sell 296,032 338.0000 BSE
27 May 2025 BNP PARIBAS FINANCIAL MARKETS Bulk Buy 296,032 338.0000 BSE
6 Dec 2024 AAKRAYA RESEARCH LLP Bulk Sell 376,606 435.0500 NSE
6 Dec 2024 AAKRAYA RESEARCH LLP Bulk Buy 376,606 434.9100 NSE

All bulk and block deals →

Ex-dateSubjectPer share (₹)Record date
— Final Dividend - Rs. - 0.5000 — —

Quarterly results, AGMs, buybacks and other board-approved business.

DatePurposeResults
21 May 2026 Financial Results/Dividend/Other business matters Yes
5 Feb 2026 Financial Results Yes
10 Nov 2025 Financial Results Yes
8 Aug 2025 Financial Results Yes
28 May 2025 Financial Results/Dividend Yes

Corporate Announcements

All 146 announcements, with search →

Exchange disclosures (NSE and BSE), most recent first.

DateCategoryAnnouncement
28 Sep 2026 Insider Trading / SAST Suraksha Diagnostic Ltd - 544293 - Closure of Trading Window
28 Sep 2026 Trading Window Suraksha Diagnostic Limited has informed the Exchange regarding the Trading Window closure pursuant to SEBI (Prohibition of Insider Trading) Regulations, 2015
24 Sep 2026 Shareholders meeting Voting Results & Scrutinizer's Report for the 21st Annual General Meeting (AGM) ofthe Company held on 22nd September, 2026
23 Sep 2026 Shareholders meeting Revised Proceedings of the 21st Annual General Meeting of the Company
22 Sep 2026 Shareholders meeting Proceedings of 21st Annual General Meeting of the Company held on September 22, 2026.
31 Aug 2026 Copy of Newspaper Publication Suraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication published today, i.e. on Monday, 31 August, 2026 with respect to the Notice of the 21st Annual General Meeting of the Company scheduled to be held on Tuesday, 22 September, 2026 and e-voting information.
27 Aug 2026 General Updates Pursuant to Regulation 36(1)(b) of the SEBI Listing Regulations, a letter to those Members whose e-mail addresses are not registered with the Company/Registrar and Share Transfer Agent (RTA), i.e. KFin Technologies Limited/Depository Participants (DPs)/Depositories is being dispatched by the Company.
27 Aug 2026 Shareholders meeting Notice of 21st Annual General Meeting to be held on September 22, 2026.
25 Aug 2026 Copy of Newspaper Publication Suraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication
25 Aug 2026 Copy of Newspaper Publication Suraksha Diagnostic Limited has informed the Exchange about Copy of Newspaper Publication

All announcements →

SWOT

Tradinity's own rule-based read of the real ratios elsewhere on this page -- not a copy of any third party's, and never a forward-looking prediction.

Strengths

  • Low financial leverage (Debt/Equity 0.01)
  • Strong revenue growth YoY (19.6%)

Weaknesses

Data unavailable.

Opportunities

Data unavailable.

Threats

  • PE above 35 (50.3) -- priced for continued strong execution

Data unavailable (no single-stock futures or options activity on record for this company).

Frequently asked questions about Suraksha Diagnostic Limited

Where is the share price?

The price at the top of this page is the last traded price from exchange data; during market hours it refreshes on its own. The Chart & Technicals section has the full price history.

Where are the financial results?

The Financials page has quarterly and annual results, ratios, cash flow and the balance sheet, on a standalone or consolidated basis.

Who owns the company?

The Ownership section shows the latest shareholding pattern from exchange filings, with promoter, FII, DII and public holdings by quarter.

Does Tradinity give buy or sell advice?

No. The scores and checklist on this page are rule-based summaries of published figures, not recommendations. Tradinity is not a registered investment adviser.